{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:30:57Z","timestamp":1726471857487},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.diagmicrobio.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T13:11:02Z","timestamp":1537189862000},"page":"159-161","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["VISA\u2013Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin"],"prefix":"10.1016","volume":"93","author":[{"given":"Louis D.","family":"Saravolatz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. M100","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2018.09.003_bb0005"},{"year":"2017","series-title":"Performance Standards for Antimicrobial Susceptibility Testing. M100","author":"Clinical and Laboratory Standards Institute (CLSI)","key":"10.1016\/j.diagmicrobio.2018.09.003_bb0010"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.diagmicrobio.2016.08.005","article-title":"Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014)","volume":"86","author":"Duncan","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0020","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1128\/AAC.03172-14","article-title":"Revised reference broth microdilution method for testing Telavancin: effect on MIC results and correlation with other testing methodologies","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0025","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diagmicrobio.2017.03.003","article-title":"Activity of telavancin against gram-positive pathogens isolated from bone and joint infections in north American, Latin American, European and Asia-Pacific nations","volume":"88","author":"Jones","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0030","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0035","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1128\/AAC.04616-14","article-title":"Telavancin In Vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets from the United States","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0040","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10096-016-2865-8","article-title":"Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)","volume":"36","author":"Mendes","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0045","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0050","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/cid\/cis492","article-title":"In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates","volume":"55","author":"Saravolatz","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0055","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.diagmicrobio.2016.12.009","article-title":"Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structured infection clinical trial isolates","volume":"87","author":"Smart","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2018.09.003_bb0060","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1128\/AAC.00773-15","article-title":"Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin and linezolid in broth microdilution MIC and one-compartment pharmacokinetic\/pharmacodynamic models","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"author":"VIBATIV\u00ae Package Insert","key":"10.1016\/j.diagmicrobio.2018.09.003_bb0065"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318303420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318303420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:52:39Z","timestamp":1546980759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318303420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0732889318303420"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.09.003","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VISA\u2013Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}